Captopril monotherapy reduced mean systolic and diastolic blood pressures by 17 and 11 mm Hg, respectively, with only 4.9% of patients requiring discontinuation due to adverse events.
Observational (n=30,515)
Yes
Does captopril monotherapy reduce blood pressure and improve quality of life in patients with hypertension?
Captopril monotherapy is an effective and well-tolerated antihypertensive treatment across diverse patient groups that also improves quality of life.
Successful long-term treatment of hypertension must include consideration of individual patients' life-style interfaced with the potential for adverse drug events. In a postmarketing surveillance study, 30,515 patients received captopril monotherapy and were evaluated by 7792 physicians. Mean systolic and diastolic blood pressures were reduced 17 and 11 mm Hg, respectively. Mean diastolic blood pressure was reduced 10% for patients with mild hypertension; larger mean reductions were noted for patients with moderate (16.5%) and severe (21.5%) hypertension. Captopril therapy was equally effective in all races (white, Hispanic, and black patients), age groups, and in isolated instances of systolic hypertension. Only 4.9% of patients reporting an adverse event required discontinuation of therapy. Headache (1.8%) and dizziness (1.6%) were the most frequently reported adverse events. Quality-of-life measures improved.
James A. Schoenberger (Thu,) conducted a observational in Hypertension (n=30,515). Captopril monotherapy was evaluated on Reduction in mean systolic and diastolic blood pressures. Captopril monotherapy reduced mean systolic and diastolic blood pressures by 17 and 11 mm Hg, respectively, with only 4.9% of patients requiring discontinuation due to adverse events.